| 1 | mean | 97,225 |
| 2 | doppler-estimated | 14 |
| 3 | médecins | 13 |
| 4 | maximum-minimum | 10 |
| 5 | clinic-daytime | 9 |
| 6 | agomelatine-placebo | 7 |
| 7 | distal-dorsal | 6 |
| 8 | 45.02 | 5 |
| 9 | arm/leg | 4 |
| 10 | logtransformed | 4 |
| 11 | physician-evaluated | 4 |
| 12 | prevalvuloplasty | 4 |
| 13 | site-adjusted | 4 |
| 14 | trough/peak | 4 |
| 15 | v-at | 4 |
| 16 | 7.5-nm | 3 |
| 17 | affected/unaffected | 3 |
| 18 | device-reported | 3 |
| 19 | distal-to-proximal | 3 |
| 20 | logarithmized | 3 |
| 21 | mean-fold | 3 |
| 22 | refractive-index | 3 |
| 23 | t3-t1 | 3 |
| 24 | ua-uv | 3 |
| 25 | φh | 3 |
| 26 | 0.000006 | 2 |
| 27 | 0.04- | 2 |
| 28 | 11-18-year | 2 |
| 29 | 13,903 | 2 |
| 30 | 164.25 | 2 |
| 31 | 174.1 | 2 |
| 32 | 3,564 | 2 |
| 33 | 4-10-year | 2 |
| 34 | 5-mg·kg | 2 |
| 35 | 77.43 | 2 |
| 36 | antibodyome | 2 |
| 37 | automated-manual | 2 |
| 38 | byk | 2 |
| 39 | cgi- | 2 |
| 40 | cpt-induced | 2 |
| 41 | distal-to-stenosis | 2 |
| 42 | diurnal/nocturnal | 2 |
| 43 | intermethods | 2 |
| 44 | irresistible | 2 |
| 45 | large-buoyant | 2 |
| 46 | lifestyle/ease | 2 |
| 47 | ls-mean | 2 |
| 48 | mg-specific | 2 |
| 49 | moxifloxacin-induced | 2 |
| 50 | pai-1and | 2 |
| 51 | placebo-estradiol | 2 |
| 52 | results-mean | 2 |
| 53 | slavonski | 2 |
| 54 | t24max | 2 |
| 55 | uccr | 2 |
| 56 | zydus | 2 |
| 57 | ≥10-point | 2 |
| 58 | +1.98 | 1 |
| 59 | +6.23 | 1 |
| 60 | +67-minute | 1 |
| 61 | -0.024×gestational | 1 |
| 62 | -2.2-1.4 | 1 |
| 63 | -28.67 | 1 |
| 64 | -71.6 | 1 |
| 65 | -9.303 | 1 |
| 66 | -δ108.6 | 1 |
| 67 | 0-2-year | 1 |
| 68 | 0.05-point | 1 |
| 69 | 0.2-1.1-fold | 1 |
| 70 | 0.21-0.42-fold | 1 |
| 71 | 0.24-0.82-fold | 1 |
| 72 | 0.25-0.86-fold | 1 |
| 73 | 0.44-point | 1 |
| 74 | 0.52-mm | 1 |
| 75 | 0.56-mm | 1 |
| 76 | 0.9-point | 1 |
| 77 | 1-17-year-old | 1 |
| 78 | 1.1-2.2-fold | 1 |
| 79 | 1.1±0.3-fold | 1 |
| 80 | 1.36° | 1 |
| 81 | 1.4±0.4-fold | 1 |
| 82 | 1.5-2.0-fold | 1 |
| 83 | 1.6±0.2 | 1 |
| 84 | 1.7-1.8-fold | 1 |
| 85 | 1040.4 | 1 |
| 86 | 106.43 | 1 |
| 87 | 1070±600iu/g | 1 |
| 88 | 11,642 | 1 |
| 89 | 11-20-year | 1 |
| 90 | 11-letter | 1 |
| 91 | 112.58 | 1 |
| 92 | 113.27 | 1 |
| 93 | 12y | 1 |
| 94 | 130.21 | 1 |
| 95 | 14.66±2.71 | 1 |
| 96 | 1412.19 | 1 |
| 97 | 15-29-year | 1 |
| 98 | 15-yard | 1 |
| 99 | 16-24-year | 1 |
| 100 | 16-25-year | 1 |
| 101 | 160.63 | 1 |
| 102 | 1830-2000 | 1 |
| 103 | 194.3 | 1 |
| 104 | 199.7 | 1 |
| 105 | 1:9.8 | 1 |
| 106 | 2-year-and-older | 1 |
| 107 | 2.3±1.5-fold | 1 |
| 108 | 2.43-point | 1 |
| 109 | 20-24-year | 1 |
| 110 | 206.29 | 1 |
| 111 | 21-30-year | 1 |
| 112 | 21.2°c | 1 |
| 113 | 21.66±4.41 | 1 |
| 114 | 216.6 | 1 |
| 115 | 230±38m | 1 |
| 116 | 236.136 | 1 |
| 117 | 24nr | 1 |
| 118 | 25-69-year | 1 |
| 119 | 254.8 | 1 |
| 120 | 260.44 | 1 |
| 121 | 2604.4 | 1 |
| 122 | 26nu | 1 |
| 123 | 280.11 | 1 |
| 124 | 291.99 | 1 |
| 125 | 294.27 | 1 |
| 126 | 2:75.6 | 1 |
| 127 | 3.5±0.9-fold | 1 |
| 128 | 3.71-fold | 1 |
| 129 | 30-49-year | 1 |
| 130 | 309.07 | 1 |
| 131 | 309.8 | 1 |
| 132 | 31-40-year | 1 |
| 133 | 31136.7 | 1 |
| 134 | 32/22°c | 1 |
| 135 | 3222.5 | 1 |
| 136 | 33.5±17.6iu/g | 1 |
| 137 | 343.1 | 1 |
| 138 | 349.1 | 1 |
| 139 | 3592.9 | 1 |
| 140 | 36,000-11,000 | 1 |
| 141 | 37.0+/-4.2 | 1 |
| 142 | 396.05 | 1 |
| 143 | 39min24s | 1 |
| 144 | 3:82.3 | 1 |
| 145 | 3:86.6 | 1 |
| 146 | 40.70 | 1 |
| 147 | 400.61 | 1 |
| 148 | 41-50-year | 1 |
| 149 | 425.26 | 1 |
| 150 | 438.83 | 1 |
| 151 | 439.1 | 1 |
| 152 | 441,870 | 1 |
| 153 | 4543.0× | 1 |
| 154 | 477.40 | 1 |
| 155 | 487.9 | 1 |
| 156 | 49.2±6.8 | 1 |
| 157 | 4:90.8 | 1 |
| 158 | 5-34-year-old | 1 |
| 159 | 50-54-year | 1 |
| 160 | 514.4 | 1 |
| 161 | 520-ms | 1 |
| 162 | 54.53±6.16 | 1 |
| 163 | 5495 | 1 |
| 164 | 55-60-years | 1 |
| 165 | 55-64-year | 1 |
| 166 | 56-72-year-old | 1 |
| 167 | 562.2 | 1 |
| 168 | 5677.47 | 1 |
| 169 | 581.6 | 1 |
| 170 | 59.74 | 1 |
| 171 | 6,6,6,6-fused | 1 |
| 172 | 6.71-fold | 1 |
| 173 | 60-64-years | 1 |
| 174 | 628.2 | 1 |
| 175 | 64.93±3.03 | 1 |
| 176 | 65+-year-old | 1 |
| 177 | 65-74-year-old | 1 |
| 178 | 68.50 | 1 |
| 179 | 74.82 | 1 |
| 180 | 762.6 | 1 |
| 181 | 79.53 | 1 |
| 182 | 7h2o | 1 |
| 183 | 8-16-year | 1 |
| 184 | 8.262 | 1 |
| 185 | 80-86-years | 1 |
| 186 | 802.70 | 1 |
| 187 | 85.6±5.9mg/d | 1 |
| 188 | 900-800 | 1 |
| 189 | 92,22.50 | 1 |
| 190 | 97.4+/-8.5mg/dl | 1 |
| 191 | =+13 | 1 |
| 192 | adrenergic-stress/rest | 1 |
| 193 | age:47.3 | 1 |
| 194 | age=187 | 1 |
| 195 | age=49.5 | 1 |
| 196 | ancova-mean | 1 |
| 197 | ao-cs | 1 |
| 198 | arousal-anxiety | 1 |
| 199 | average±sd | 1 |
| 200 | beta-migrating | 1 |
| 201 | bevacizumab-ranibizumab | 1 |
| 202 | bmi-28.6 | 1 |
| 203 | bmi/median | 1 |
| 204 | bmi=24.1 | 1 |
| 205 | bmi=31 | 1 |
| 206 | bmi=32.7 | 1 |
| 207 | bmi=34.8 | 1 |
| 208 | bmi=35.3 | 1 |
| 209 | bmi=37 | 1 |
| 210 | bmi=46.8 | 1 |
| 211 | bw=107 | 1 |
| 212 | bw=277 | 1 |
| 213 | cbfv/mean | 1 |
| 214 | ci=δhr/predicted | 1 |
| 215 | comfortable/fast | 1 |
| 216 | coming-of | 1 |
| 217 | controls-112.9 | 1 |
| 218 | cpap-mad | 1 |
| 219 | cpt/modified | 1 |
| 220 | cross-dimension | 1 |
| 221 | crossed-uncrossed | 1 |
| 222 | demen | 1 |
| 223 | deviant-minus-standard | 1 |
| 224 | diagnostic/non-diagnostic | 1 |
| 225 | donepezil-placebo | 1 |
| 226 | double-chambered | 1 |
| 227 | dualer | 1 |
| 228 | ec50=13.9 | 1 |
| 229 | ec50=26.0 | 1 |
| 230 | edv=2.22 | 1 |
| 231 | fast-to-fed | 1 |
| 232 | fbg=4.77 | 1 |
| 233 | fev1:76 | 1 |
| 234 | fm=47.5 | 1 |
| 235 | frequency=14 | 1 |
| 236 | frq/ | 1 |
| 237 | g2=2.81 | 1 |
| 238 | groups.mean | 1 |
| 239 | gsk2190915-placebo | 1 |
| 240 | height=177.7 | 1 |
| 241 | i.e.the | 1 |
| 242 | ii-normal | 1 |
| 243 | iii-borderline | 1 |
| 244 | intraparticipant | 1 |
| 245 | iv-low | 1 |
| 246 | k4/k5 | 1 |
| 247 | k=252 | 1 |
| 248 | lean/obese | 1 |
| 249 | leastsquares | 1 |
| 250 | less-than-65-y | 1 |
| 251 | mcavmean/mean | 1 |
| 252 | md=-48.2 | 1 |
| 253 | md=-9.9 | 1 |
| 254 | mk-8998-placebo | 1 |
| 255 | mri/planning | 1 |
| 256 | nct00953186 | 1 |
| 257 | non-potty-trained | 1 |
| 258 | nptr- | 1 |
| 259 | ntfe=3.5 | 1 |
| 260 | olanzapine-placebo | 1 |
| 261 | paired-risk | 1 |
| 262 | percapita | 1 |
| 263 | peri-retirement | 1 |
| 264 | physician-assigned | 1 |
| 265 | phytofluene | 1 |
| 266 | plano-parallel | 1 |
| 267 | pooled-risk | 1 |
| 268 | portage | 1 |
| 269 | post-treatment=0.87 | 1 |
| 270 | pre-genetic | 1 |
| 271 | pre-presbyopic | 1 |
| 272 | pre-to-follow-up | 1 |
| 273 | rate=64.9 | 1 |
| 274 | rate=87 | 1 |
| 275 | ri=0.89 | 1 |
| 276 | salmeterol-placebo | 1 |
| 277 | sbp-mean | 1 |
| 278 | sc10=93.4 | 1 |
| 279 | score=53 | 1 |
| 280 | sfc-mon | 1 |
| 281 | stress-buffer | 1 |
| 282 | tat-att | 1 |
| 283 | tenney-parker | 1 |
| 284 | teton | 1 |
| 285 | triple-pass | 1 |
| 286 | vemax/40 | 1 |
| 287 | vmax:120 | 1 |
| 288 | vocable | 1 |
| 289 | µ=32.50 | 1 |
| 290 | δhct=-5.67 | 1 |
| 291 | δhospital | 1 |
| 292 | ∼20/125 | 1 |
| 293 | ∼20/32 | 1 |
| 294 | ≥15.8-point | 1 |
| 295 | ≥16-point | 1 |
| 296 | ≥20-mm | 1 |
| 297 | ≥55-year | 1 |
| 298 | ⩾95th | 1 |
| 1 | +1.98 | 1 |
| 2 | +6.23 | 1 |
| 3 | +67-minute | 1 |
| 4 | -0.024×gestational | 1 |
| 5 | -2.2-1.4 | 1 |
| 6 | -28.67 | 1 |
| 7 | -71.6 | 1 |
| 8 | -9.303 | 1 |
| 9 | -δ108.6 | 1 |
| 10 | 0-2-year | 1 |
| 11 | 0.000006 | 2 |
| 12 | 0.04- | 2 |
| 13 | 0.05-point | 1 |
| 14 | 0.2-1.1-fold | 1 |
| 15 | 0.21-0.42-fold | 1 |
| 16 | 0.24-0.82-fold | 1 |
| 17 | 0.25-0.86-fold | 1 |
| 18 | 0.44-point | 1 |
| 19 | 0.52-mm | 1 |
| 20 | 0.56-mm | 1 |
| 21 | 0.9-point | 1 |
| 22 | 1-17-year-old | 1 |
| 23 | 1.1-2.2-fold | 1 |
| 24 | 1.1±0.3-fold | 1 |
| 25 | 1.36° | 1 |
| 26 | 1.4±0.4-fold | 1 |
| 27 | 1.5-2.0-fold | 1 |
| 28 | 1.6±0.2 | 1 |
| 29 | 1.7-1.8-fold | 1 |
| 30 | 1040.4 | 1 |
| 31 | 106.43 | 1 |
| 32 | 1070±600iu/g | 1 |
| 33 | 11,642 | 1 |
| 34 | 11-18-year | 2 |
| 35 | 11-20-year | 1 |
| 36 | 11-letter | 1 |
| 37 | 112.58 | 1 |
| 38 | 113.27 | 1 |
| 39 | 12y | 1 |
| 40 | 13,903 | 2 |
| 41 | 130.21 | 1 |
| 42 | 14.66±2.71 | 1 |
| 43 | 1412.19 | 1 |
| 44 | 15-29-year | 1 |
| 45 | 15-yard | 1 |
| 46 | 16-24-year | 1 |
| 47 | 16-25-year | 1 |
| 48 | 160.63 | 1 |
| 49 | 164.25 | 2 |
| 50 | 174.1 | 2 |
| 51 | 1830-2000 | 1 |
| 52 | 194.3 | 1 |
| 53 | 199.7 | 1 |
| 54 | 1:9.8 | 1 |
| 55 | 2-year-and-older | 1 |
| 56 | 2.3±1.5-fold | 1 |
| 57 | 2.43-point | 1 |
| 58 | 20-24-year | 1 |
| 59 | 206.29 | 1 |
| 60 | 21-30-year | 1 |
| 61 | 21.2°c | 1 |
| 62 | 21.66±4.41 | 1 |
| 63 | 216.6 | 1 |
| 64 | 230±38m | 1 |
| 65 | 236.136 | 1 |
| 66 | 24nr | 1 |
| 67 | 25-69-year | 1 |
| 68 | 254.8 | 1 |
| 69 | 260.44 | 1 |
| 70 | 2604.4 | 1 |
| 71 | 26nu | 1 |
| 72 | 280.11 | 1 |
| 73 | 291.99 | 1 |
| 74 | 294.27 | 1 |
| 75 | 2:75.6 | 1 |
| 76 | 3,564 | 2 |
| 77 | 3.5±0.9-fold | 1 |
| 78 | 3.71-fold | 1 |
| 79 | 30-49-year | 1 |
| 80 | 309.07 | 1 |
| 81 | 309.8 | 1 |
| 82 | 31-40-year | 1 |
| 83 | 31136.7 | 1 |
| 84 | 32/22°c | 1 |
| 85 | 3222.5 | 1 |
| 86 | 33.5±17.6iu/g | 1 |
| 87 | 343.1 | 1 |
| 88 | 349.1 | 1 |
| 89 | 3592.9 | 1 |
| 90 | 36,000-11,000 | 1 |
| 91 | 37.0+/-4.2 | 1 |
| 92 | 396.05 | 1 |
| 93 | 39min24s | 1 |
| 94 | 3:82.3 | 1 |
| 95 | 3:86.6 | 1 |
| 96 | 4-10-year | 2 |
| 97 | 40.70 | 1 |
| 98 | 400.61 | 1 |
| 99 | 41-50-year | 1 |
| 100 | 425.26 | 1 |
| 101 | 438.83 | 1 |
| 102 | 439.1 | 1 |
| 103 | 441,870 | 1 |
| 104 | 45.02 | 5 |
| 105 | 4543.0× | 1 |
| 106 | 477.40 | 1 |
| 107 | 487.9 | 1 |
| 108 | 49.2±6.8 | 1 |
| 109 | 4:90.8 | 1 |
| 110 | 5-34-year-old | 1 |
| 111 | 5-mg·kg | 2 |
| 112 | 50-54-year | 1 |
| 113 | 514.4 | 1 |
| 114 | 520-ms | 1 |
| 115 | 54.53±6.16 | 1 |
| 116 | 5495 | 1 |
| 117 | 55-60-years | 1 |
| 118 | 55-64-year | 1 |
| 119 | 56-72-year-old | 1 |
| 120 | 562.2 | 1 |
| 121 | 5677.47 | 1 |
| 122 | 581.6 | 1 |
| 123 | 59.74 | 1 |
| 124 | 6,6,6,6-fused | 1 |
| 125 | 6.71-fold | 1 |
| 126 | 60-64-years | 1 |
| 127 | 628.2 | 1 |
| 128 | 64.93±3.03 | 1 |
| 129 | 65+-year-old | 1 |
| 130 | 65-74-year-old | 1 |
| 131 | 68.50 | 1 |
| 132 | 7.5-nm | 3 |
| 133 | 74.82 | 1 |
| 134 | 762.6 | 1 |
| 135 | 77.43 | 2 |
| 136 | 79.53 | 1 |
| 137 | 7h2o | 1 |
| 138 | 8-16-year | 1 |
| 139 | 8.262 | 1 |
| 140 | 80-86-years | 1 |
| 141 | 802.70 | 1 |
| 142 | 85.6±5.9mg/d | 1 |
| 143 | 900-800 | 1 |
| 144 | 92,22.50 | 1 |
| 145 | 97.4+/-8.5mg/dl | 1 |
| 146 | =+13 | 1 |
| 147 | adrenergic-stress/rest | 1 |
| 148 | affected/unaffected | 3 |
| 149 | age:47.3 | 1 |
| 150 | age=187 | 1 |
| 151 | age=49.5 | 1 |
| 152 | agomelatine-placebo | 7 |
| 153 | ancova-mean | 1 |
| 154 | antibodyome | 2 |
| 155 | ao-cs | 1 |
| 156 | arm/leg | 4 |
| 157 | arousal-anxiety | 1 |
| 158 | automated-manual | 2 |
| 159 | average±sd | 1 |
| 160 | beta-migrating | 1 |
| 161 | bevacizumab-ranibizumab | 1 |
| 162 | bmi-28.6 | 1 |
| 163 | bmi/median | 1 |
| 164 | bmi=24.1 | 1 |
| 165 | bmi=31 | 1 |
| 166 | bmi=32.7 | 1 |
| 167 | bmi=34.8 | 1 |
| 168 | bmi=35.3 | 1 |
| 169 | bmi=37 | 1 |
| 170 | bmi=46.8 | 1 |
| 171 | bw=107 | 1 |
| 172 | bw=277 | 1 |
| 173 | byk | 2 |
| 174 | cbfv/mean | 1 |
| 175 | cgi- | 2 |
| 176 | ci=δhr/predicted | 1 |
| 177 | clinic-daytime | 9 |
| 178 | comfortable/fast | 1 |
| 179 | coming-of | 1 |
| 180 | controls-112.9 | 1 |
| 181 | cpap-mad | 1 |
| 182 | cpt-induced | 2 |
| 183 | cpt/modified | 1 |
| 184 | cross-dimension | 1 |
| 185 | crossed-uncrossed | 1 |
| 186 | demen | 1 |
| 187 | deviant-minus-standard | 1 |
| 188 | device-reported | 3 |
| 189 | diagnostic/non-diagnostic | 1 |
| 190 | distal-dorsal | 6 |
| 191 | distal-to-proximal | 3 |
| 192 | distal-to-stenosis | 2 |
| 193 | diurnal/nocturnal | 2 |
| 194 | donepezil-placebo | 1 |
| 195 | doppler-estimated | 14 |
| 196 | double-chambered | 1 |
| 197 | dualer | 1 |
| 198 | ec50=13.9 | 1 |
| 199 | ec50=26.0 | 1 |
| 200 | edv=2.22 | 1 |
| 201 | fast-to-fed | 1 |
| 202 | fbg=4.77 | 1 |
| 203 | fev1:76 | 1 |
| 204 | fm=47.5 | 1 |
| 205 | frequency=14 | 1 |
| 206 | frq/ | 1 |
| 207 | g2=2.81 | 1 |
| 208 | groups.mean | 1 |
| 209 | gsk2190915-placebo | 1 |
| 210 | height=177.7 | 1 |
| 211 | i.e.the | 1 |
| 212 | ii-normal | 1 |
| 213 | iii-borderline | 1 |
| 214 | intermethods | 2 |
| 215 | intraparticipant | 1 |
| 216 | irresistible | 2 |
| 217 | iv-low | 1 |
| 218 | k4/k5 | 1 |
| 219 | k=252 | 1 |
| 220 | large-buoyant | 2 |
| 221 | lean/obese | 1 |
| 222 | leastsquares | 1 |
| 223 | less-than-65-y | 1 |
| 224 | lifestyle/ease | 2 |
| 225 | logarithmized | 3 |
| 226 | logtransformed | 4 |
| 227 | ls-mean | 2 |
| 228 | maximum-minimum | 10 |
| 229 | mcavmean/mean | 1 |
| 230 | md=-48.2 | 1 |
| 231 | md=-9.9 | 1 |
| 232 | mean | 97,225 |
| 233 | mean-fold | 3 |
| 234 | mg-specific | 2 |
| 235 | mk-8998-placebo | 1 |
| 236 | moxifloxacin-induced | 2 |
| 237 | mri/planning | 1 |
| 238 | médecins | 13 |
| 239 | nct00953186 | 1 |
| 240 | non-potty-trained | 1 |
| 241 | nptr- | 1 |
| 242 | ntfe=3.5 | 1 |
| 243 | olanzapine-placebo | 1 |
| 244 | pai-1and | 2 |
| 245 | paired-risk | 1 |
| 246 | percapita | 1 |
| 247 | peri-retirement | 1 |
| 248 | physician-assigned | 1 |
| 249 | physician-evaluated | 4 |
| 250 | phytofluene | 1 |
| 251 | placebo-estradiol | 2 |
| 252 | plano-parallel | 1 |
| 253 | pooled-risk | 1 |
| 254 | portage | 1 |
| 255 | post-treatment=0.87 | 1 |
| 256 | pre-genetic | 1 |
| 257 | pre-presbyopic | 1 |
| 258 | pre-to-follow-up | 1 |
| 259 | prevalvuloplasty | 4 |
| 260 | rate=64.9 | 1 |
| 261 | rate=87 | 1 |
| 262 | refractive-index | 3 |
| 263 | results-mean | 2 |
| 264 | ri=0.89 | 1 |
| 265 | salmeterol-placebo | 1 |
| 266 | sbp-mean | 1 |
| 267 | sc10=93.4 | 1 |
| 268 | score=53 | 1 |
| 269 | sfc-mon | 1 |
| 270 | site-adjusted | 4 |
| 271 | slavonski | 2 |
| 272 | stress-buffer | 1 |
| 273 | t24max | 2 |
| 274 | t3-t1 | 3 |
| 275 | tat-att | 1 |
| 276 | tenney-parker | 1 |
| 277 | teton | 1 |
| 278 | triple-pass | 1 |
| 279 | trough/peak | 4 |
| 280 | ua-uv | 3 |
| 281 | uccr | 2 |
| 282 | v-at | 4 |
| 283 | vemax/40 | 1 |
| 284 | vmax:120 | 1 |
| 285 | vocable | 1 |
| 286 | zydus | 2 |
| 287 | µ=32.50 | 1 |
| 288 | δhct=-5.67 | 1 |
| 289 | δhospital | 1 |
| 290 | φh | 3 |
| 291 | ∼20/125 | 1 |
| 292 | ∼20/32 | 1 |
| 293 | ≥10-point | 2 |
| 294 | ≥15.8-point | 1 |
| 295 | ≥16-point | 1 |
| 296 | ≥20-mm | 1 |
| 297 | ≥55-year | 1 |
| 298 | ⩾95th | 1 |
| 1 | 0.04- | 2 |
| 2 | cgi- | 2 |
| 3 | nptr- | 1 |
| 4 | frq/ | 1 |
| 5 | ec50=26.0 | 1 |
| 6 | 36,000-11,000 | 1 |
| 7 | 1830-2000 | 1 |
| 8 | 900-800 | 1 |
| 9 | vmax:120 | 1 |
| 10 | 477.40 | 1 |
| 11 | vemax/40 | 1 |
| 12 | 92,22.50 | 1 |
| 13 | µ=32.50 | 1 |
| 14 | 68.50 | 1 |
| 15 | 40.70 | 1 |
| 16 | 802.70 | 1 |
| 17 | 441,870 | 1 |
| 18 | 343.1 | 1 |
| 19 | bmi=24.1 | 1 |
| 20 | 174.1 | 2 |
| 21 | 439.1 | 1 |
| 22 | 349.1 | 1 |
| 23 | 280.11 | 1 |
| 24 | 130.21 | 1 |
| 25 | bmi=31 | 1 |
| 26 | 21.66±4.41 | 1 |
| 27 | 400.61 | 1 |
| 28 | 14.66±2.71 | 1 |
| 29 | g2=2.81 | 1 |
| 30 | t3-t1 | 3 |
| 31 | 1.6±0.2 | 1 |
| 32 | 562.2 | 1 |
| 33 | 37.0+/-4.2 | 1 |
| 34 | 628.2 | 1 |
| 35 | md=-48.2 | 1 |
| 36 | 45.02 | 5 |
| 37 | edv=2.22 | 1 |
| 38 | ∼20/32 | 1 |
| 39 | 11,642 | 1 |
| 40 | k=252 | 1 |
| 41 | 8.262 | 1 |
| 42 | 74.82 | 1 |
| 43 | 3:82.3 | 1 |
| 44 | 194.3 | 1 |
| 45 | bmi=35.3 | 1 |
| 46 | age:47.3 | 1 |
| 47 | 64.93±3.03 | 1 |
| 48 | -9.303 | 1 |
| 49 | 13,903 | 2 |
| 50 | =+13 | 1 |
| 51 | +6.23 | 1 |
| 52 | 106.43 | 1 |
| 53 | 77.43 | 2 |
| 54 | 79.53 | 1 |
| 55 | score=53 | 1 |
| 56 | 160.63 | 1 |
| 57 | 438.83 | 1 |
| 58 | 1040.4 | 1 |
| 59 | -2.2-1.4 | 1 |
| 60 | sc10=93.4 | 1 |
| 61 | 2604.4 | 1 |
| 62 | 514.4 | 1 |
| 63 | frequency=14 | 1 |
| 64 | 260.44 | 1 |
| 65 | 3,564 | 2 |
| 66 | 59.74 | 1 |
| 67 | 3222.5 | 1 |
| 68 | ntfe=3.5 | 1 |
| 69 | fm=47.5 | 1 |
| 70 | age=49.5 | 1 |
| 71 | 396.05 | 1 |
| 72 | 164.25 | 2 |
| 73 | ∼20/125 | 1 |
| 74 | 5495 | 1 |
| 75 | k4/k5 | 1 |
| 76 | -71.6 | 1 |
| 77 | 581.6 | 1 |
| 78 | 762.6 | 1 |
| 79 | 2:75.6 | 1 |
| 80 | 216.6 | 1 |
| 81 | 3:86.6 | 1 |
| 82 | -δ108.6 | 1 |
| 83 | bmi-28.6 | 1 |
| 84 | 0.000006 | 2 |
| 85 | 54.53±6.16 | 1 |
| 86 | 425.26 | 1 |
| 87 | 236.136 | 1 |
| 88 | fev1:76 | 1 |
| 89 | nct00953186 | 1 |
| 90 | bmi=32.7 | 1 |
| 91 | 31136.7 | 1 |
| 92 | height=177.7 | 1 |
| 93 | 199.7 | 1 |
| 94 | 309.07 | 1 |
| 95 | bw=107 | 1 |
| 96 | 113.27 | 1 |
| 97 | 294.27 | 1 |
| 98 | bmi=37 | 1 |
| 99 | 5677.47 | 1 |
| 100 | δhct=-5.67 | 1 |
| 101 | -28.67 | 1 |
| 102 | fbg=4.77 | 1 |
| 103 | bw=277 | 1 |
| 104 | post-treatment=0.87 | 1 |
| 105 | age=187 | 1 |
| 106 | rate=87 | 1 |
| 107 | 4:90.8 | 1 |
| 108 | bmi=34.8 | 1 |
| 109 | 254.8 | 1 |
| 110 | bmi=46.8 | 1 |
| 111 | 49.2±6.8 | 1 |
| 112 | 309.8 | 1 |
| 113 | 1:9.8 | 1 |
| 114 | 112.58 | 1 |
| 115 | +1.98 | 1 |
| 116 | controls-112.9 | 1 |
| 117 | 3592.9 | 1 |
| 118 | ec50=13.9 | 1 |
| 119 | rate=64.9 | 1 |
| 120 | 487.9 | 1 |
| 121 | md=-9.9 | 1 |
| 122 | 1412.19 | 1 |
| 123 | 206.29 | 1 |
| 124 | ri=0.89 | 1 |
| 125 | 291.99 | 1 |
| 126 | percapita | 1 |
| 127 | bevacizumab-ranibizumab | 1 |
| 128 | mg-specific | 2 |
| 129 | pre-presbyopic | 1 |
| 130 | pre-genetic | 1 |
| 131 | diagnostic/non-diagnostic | 1 |
| 132 | 21.2°c | 1 |
| 133 | 32/22°c | 1 |
| 134 | 85.6±5.9mg/d | 1 |
| 135 | cpap-mad | 1 |
| 136 | moxifloxacin-induced | 2 |
| 137 | cpt-induced | 2 |
| 138 | fast-to-fed | 1 |
| 139 | cpt/modified | 1 |
| 140 | logtransformed | 4 |
| 141 | physician-assigned | 1 |
| 142 | non-potty-trained | 1 |
| 143 | double-chambered | 1 |
| 144 | crossed-uncrossed | 1 |
| 145 | 6,6,6,6-fused | 1 |
| 146 | doppler-estimated | 14 |
| 147 | physician-evaluated | 4 |
| 148 | affected/unaffected | 3 |
| 149 | ci=δhr/predicted | 1 |
| 150 | device-reported | 3 |
| 151 | site-adjusted | 4 |
| 152 | logarithmized | 3 |
| 153 | 65+-year-old | 1 |
| 154 | 56-72-year-old | 1 |
| 155 | 5-34-year-old | 1 |
| 156 | 65-74-year-old | 1 |
| 157 | 1-17-year-old | 1 |
| 158 | 1.5-2.0-fold | 1 |
| 159 | 0.2-1.1-fold | 1 |
| 160 | 3.71-fold | 1 |
| 161 | 6.71-fold | 1 |
| 162 | 1.1-2.2-fold | 1 |
| 163 | 0.21-0.42-fold | 1 |
| 164 | 0.24-0.82-fold | 1 |
| 165 | 1.1±0.3-fold | 1 |
| 166 | 1.4±0.4-fold | 1 |
| 167 | 2.3±1.5-fold | 1 |
| 168 | 0.25-0.86-fold | 1 |
| 169 | 1.7-1.8-fold | 1 |
| 170 | 3.5±0.9-fold | 1 |
| 171 | mean-fold | 3 |
| 172 | pai-1and | 2 |
| 173 | deviant-minus-standard | 1 |
| 174 | 15-yard | 1 |
| 175 | average±sd | 1 |
| 176 | portage | 1 |
| 177 | i.e.the | 1 |
| 178 | vocable | 1 |
| 179 | irresistible | 2 |
| 180 | clinic-daytime | 9 |
| 181 | antibodyome | 2 |
| 182 | phytofluene | 1 |
| 183 | iii-borderline | 1 |
| 184 | lifestyle/ease | 2 |
| 185 | lean/obese | 1 |
| 186 | +67-minute | 1 |
| 187 | coming-of | 1 |
| 188 | 1070±600iu/g | 1 |
| 189 | 33.5±17.6iu/g | 1 |
| 190 | arm/leg | 4 |
| 191 | 5-mg·kg | 2 |
| 192 | mri/planning | 1 |
| 193 | beta-migrating | 1 |
| 194 | ⩾95th | 1 |
| 195 | φh | 3 |
| 196 | slavonski | 2 |
| 197 | trough/peak | 4 |
| 198 | pooled-risk | 1 |
| 199 | paired-risk | 1 |
| 200 | byk | 2 |
| 201 | distal-to-proximal | 3 |
| 202 | ii-normal | 1 |
| 203 | -0.024×gestational | 1 |
| 204 | diurnal/nocturnal | 2 |
| 205 | distal-dorsal | 6 |
| 206 | δhospital | 1 |
| 207 | automated-manual | 2 |
| 208 | 97.4+/-8.5mg/dl | 1 |
| 209 | plano-parallel | 1 |
| 210 | placebo-estradiol | 2 |
| 211 | 230±38m | 1 |
| 212 | ≥20-mm | 1 |
| 213 | 0.52-mm | 1 |
| 214 | 0.56-mm | 1 |
| 215 | 7.5-nm | 3 |
| 216 | maximum-minimum | 10 |
| 217 | mean | 97,225 |
| 218 | ancova-mean | 1 |
| 219 | sbp-mean | 1 |
| 220 | ls-mean | 2 |
| 221 | results-mean | 2 |
| 222 | groups.mean | 1 |
| 223 | mcavmean/mean | 1 |
| 224 | cbfv/mean | 1 |
| 225 | bmi/median | 1 |
| 226 | demen | 1 |
| 227 | cross-dimension | 1 |
| 228 | sfc-mon | 1 |
| 229 | teton | 1 |
| 230 | 7h2o | 1 |
| 231 | gsk2190915-placebo | 1 |
| 232 | mk-8998-placebo | 1 |
| 233 | olanzapine-placebo | 1 |
| 234 | agomelatine-placebo | 7 |
| 235 | donepezil-placebo | 1 |
| 236 | salmeterol-placebo | 1 |
| 237 | pre-to-follow-up | 1 |
| 238 | 4-10-year | 2 |
| 239 | 11-20-year | 1 |
| 240 | 21-30-year | 1 |
| 241 | 31-40-year | 1 |
| 242 | 41-50-year | 1 |
| 243 | 0-2-year | 1 |
| 244 | 20-24-year | 1 |
| 245 | 16-24-year | 1 |
| 246 | 50-54-year | 1 |
| 247 | 55-64-year | 1 |
| 248 | 16-25-year | 1 |
| 249 | ≥55-year | 1 |
| 250 | 8-16-year | 1 |
| 251 | 11-18-year | 2 |
| 252 | 15-29-year | 1 |
| 253 | 30-49-year | 1 |
| 254 | 25-69-year | 1 |
| 255 | uccr | 2 |
| 256 | 2-year-and-older | 1 |
| 257 | stress-buffer | 1 |
| 258 | tenney-parker | 1 |
| 259 | dualer | 1 |
| 260 | 11-letter | 1 |
| 261 | 24nr | 1 |
| 262 | 39min24s | 1 |
| 263 | ao-cs | 1 |
| 264 | intermethods | 2 |
| 265 | leastsquares | 1 |
| 266 | distal-to-stenosis | 2 |
| 267 | 520-ms | 1 |
| 268 | médecins | 13 |
| 269 | 55-60-years | 1 |
| 270 | 60-64-years | 1 |
| 271 | 80-86-years | 1 |
| 272 | triple-pass | 1 |
| 273 | zydus | 2 |
| 274 | v-at | 4 |
| 275 | intraparticipant | 1 |
| 276 | large-buoyant | 2 |
| 277 | peri-retirement | 1 |
| 278 | ≥10-point | 2 |
| 279 | 2.43-point | 1 |
| 280 | 0.44-point | 1 |
| 281 | 0.05-point | 1 |
| 282 | ≥16-point | 1 |
| 283 | ≥15.8-point | 1 |
| 284 | 0.9-point | 1 |
| 285 | comfortable/fast | 1 |
| 286 | adrenergic-stress/rest | 1 |
| 287 | tat-att | 1 |
| 288 | 26nu | 1 |
| 289 | ua-uv | 3 |
| 290 | iv-low | 1 |
| 291 | t24max | 2 |
| 292 | refractive-index | 3 |
| 293 | less-than-65-y | 1 |
| 294 | 12y | 1 |
| 295 | arousal-anxiety | 1 |
| 296 | prevalvuloplasty | 4 |
| 297 | 4543.0× | 1 |
| 298 | 1.36° | 1 |